Blog
RSS FeedPosted by Michael Wonder on 10 Aug 2021
Implementing outcomes based managed entry agreements for rare disease treatments: nusinersen and tisagenlecleucel
10 August 2021 - Enthusiasm for the use of outcomes based managed entry agreements to manage uncertainties apparent at the time ...
Posted by Michael Wonder on 17 May 2021
Optimising managed access: lessons from the Cancer Drugs Fund
14 May 2021 - The desire, opportunity, and willingness to increase access to potentially life saving cancer treatments has mounted in ...
Posted by Michael Wonder on 01 Feb 2021
Determinants of managed entry agreements in the context of health technology assessment: a comparative analysis of oncology therapies in four countries
29 January 2021 - Managed entry agreements are increasingly used to address uncertainties arising in the health technology assessment process due ...
Posted by Michael Wonder on 15 Jul 2020
The impact of managed entry agreements on pharmaceutical prices
6 July 2020 - Managed entry agreements have been used for several years, with the aim of curbing the growth of ...
Posted by Michael Wonder on 02 Jun 2018
Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience
31 May 2018 - Innovative pricing agreements for medicines have been used in European markets for more than 20 years, ...
Posted by Michael Wonder on 14 Jan 2018
A managed access approach to appraising new cancer drugs in England
12 January 2018 - The changing regulatory landscape brings new challenges to health technology assessment. Marketing authorisations are being granted as ...